331. 特発性多中心性キャッスルマン病 Idiopathic multicentric castleman disease Clinical trials / Disease details


臨床試験数 : 33 薬物数 : 46 - (DrugBank : 25) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 155

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT2071190029
25/05/202009/10/2019Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant)Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant) idiopathic multicentric Castleman's disease
Castleman's disease
Treatment: Sirolimus 2 mg po once/day.
Control: Placebo given orally once daily
Kawakami AtsushiNULLNot Recruiting>= 18age oldNot applicableBoth20Phase 2Japan
2NCT03933904
(ClinicalTrials.gov)
September 25, 201929/4/2019Sirolimus in Previously Treated Idiopathic Multicentric Castleman DiseaseA Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman DiseaseCastleman Disease;Castleman's Disease, MulticentricDrug: SirolimusUniversity of PennsylvaniaNULLRecruiting18 Years80 YearsAll24Phase 2United States
3NCT00092222
(ClinicalTrials.gov)
October 28, 200421/9/2004Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityTargeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease ActivityLymphoproliferative Disorder;HHV-8;Malignancy;HIVDrug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin;Drug: Bortezomib;Drug: Valganciclovir;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide;Drug: Filgrastim (G-CSF);Drug: Prednisone;Drug: Sirolimus;Other: Observation OnlyNational Cancer Institute (NCI)NULLRecruiting18 YearsN/AAll80Phase 2United States